Oncternal Therapeutics, Inc.
ONCT · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $1 | $1 | $4 | $3 |
| % Growth | -47.3% | -65.5% | 27.9% | – |
| Cost of Goods Sold | $30 | $0 | $0 | $12 |
| Gross Profit | -$29 | $1 | $4 | -$9 |
| % Margin | -3,690.2% | 88% | 96.1% | -255.6% |
| R&D Expenses | $30 | $33 | $24 | $13 |
| G&A Expenses | $13 | $13 | $12 | $8 |
| SG&A Expenses | $13 | $13 | $12 | $8 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$30 | -$1 | -$4 | -$3 |
| Operating Expenses | $13 | $45 | $31 | $18 |
| Operating Income | -$42 | -$45 | -$31 | -$18 |
| % Margin | -5,313.9% | -3,016.6% | -726.9% | -519.8% |
| Other Income/Exp. Net | $2 | $1 | $0 | $0 |
| Pre-Tax Income | -$39 | -$44 | -$31 | -$17 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$39 | -$43 | -$31 | -$17 |
| % Margin | -5,029.2% | -2,912.3% | -725.4% | -509.9% |
| EPS | -13.43 | -16.5 | -1.94 | -0.69 |
| % Growth | 18.6% | -750.5% | -181.2% | – |
| EPS Diluted | -13.43 | -16.5 | -1.94 | -0.69 |
| Weighted Avg Shares Out | 3 | 3 | 16 | 25 |
| Weighted Avg Shares Out Dil | 3 | 3 | 16 | 25 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $1 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $42 | $0 | $0 | $0 |
| EBITDA | $2 | -$45 | -$31 | -$17 |
| % Margin | 284.7% | -3,016.6% | -722.2% | -515.3% |